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A series of 4-[(triazolyl)methoxy]phenyl analogs of the phenoxyphenyl-substituted thiirane SB-
3CT 1 was evaluated for its ability to inhibit gelatinases, members of the matrix 
metalloproteinase family of enzymes. The triazole segment of these inhibitors was assembled 
using the Meldal-Sharpless copper-catalyzed Huisgen dipolar cycloaddition of an azide and a 
terminal alkyne. While these triazole derivatives possessed fair activity as gelatinase inhibitors, 
an intermediate used in the dipolar cycloaddition, 4-(propargyloxy)phenyl derivative 2, showed 
very good activity (>50% inhibitory activity following a 3 h pre-incubation of 2 at a 
concentration of 3 µM) as an inhibitor of human matrix metalloproteinase-2. 
 






The “click” reactions have opened new opportunities in medicinal chemistry for lead 
optimization as a result of the ability of these reactions to rapidly construct analog libraries.1-4 
The copper-catalyzed Huisgen 1,3-dipolar cycloaddition of alkynes and azides, yielding 1,4-
disubstituted 1,2,3-triazoles, is the gold standard of a click reaction.5-8 
Triazoles possess a number of desirable features in developing the structure-activity 
correlations used in medicinal chemistry. The aromatic stabilization of the triazole renders the 
ring stable to reduction, oxidation, and both acid- and base-catalyzed hydrolysis. Accordingly, 
triazoles are relatively resistant to metabolic degradation.9,10 In addition, their high dipole 
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moment facilitates formation of hydrogen bond through their nitrogen atoms, as well as their 
participation in dipole–dipole and π-stacking interactions with their macromolecular target.  
Matrix metalloproteinases (MMPs) belong to a family of closely related zinc-dependent 
endopeptidases that are implicated in the cleavage of extracellular matrix proteins. MMPs play a 
crucial role in several pathological and physiological processes such as tissue remodeling, 
embryonic development and wound healing.11-13 As a consequence, a number of disease 
processes are associated with their misregulation and uncontrolled activities including 
neurological disorders, arthritis, cardiovascular diseases, and cancer. Given the involvement of 
the MMPs in these pathologies, MMP-specific inhibitors would be very valuable as therapeutic 
agents.14  
We have previously described the synthesis, MMP inhibitory activity,15,16 mechanism17,18 and 
metabolism studies19,20 of the thiirane-containing compound 1, which is a potent (nanomolar) 
and selective mechanism-based inhibitor of the gelatinases (MMP-2 and MMP-9). This inhibitor 
is the only mechanism-based inhibitor known for any MMP, and operates by a distinct 
mechanism that gives rise to stable complex with the gelatinases involving thiolate coordination 
to the active site zinc atom. Its unique features include a biphenyl moiety that fits into the S1' 
pocket of these gelatinases, and a thiirane ring that undergoes gelatinase-catalyzed ring opening 





Figure 1. Stereoview representation of compound (R)-1 (top) and (S)-1 (bottom)—both 
enantiomers are equally active against gelatinases—in the active site of MMP-2. The zinc ion is 
shown as a purple sphere. 
 
Despite its rapid metabolism in mice20 resulting in low systemic concentrations,19 as a result of 
its high potency and the generation of an active metabolite, compound 1 is active in vivo in 
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several animal models of disease.22,23 However, due to its additional liability of poor aqueous 
solubility, compound 1 is precluded from moving forward as a drug candidate. For these reasons, 
we were interested in the discovery of heteroaryl replacements within the phenoxyphenyl 
segment to simultaneously impart improved metabolic stability and improved water solubility. 
Our evaluation of the CuAAC reaction toward this objective is described. 
 
 
Results and Discussion 
 
As part of our continuing efforts to explore thiirane-based MMP inhibitors, and with the aim to 
find an inhibitor with improved pharmacokinetic properties, we used the CuAAC click reaction 






We knew that the core 4-[(thiiran-2-ylmethyl)sulfonyl]phenyl moiety of 1 (Figure 2) was 
essential to retain the inhibitory activity against gelatinases. Hence, we concentrated on 
evaluating alternative ring substitutions (R of Figure 2) in order to identify a gelatinase inhibitor 
with improved properties. As MMP-2 has a hydrophobic tunnel-like S1’pocket with an open 
bottom, the possibility of elongating the molecule by the 1,3-dipolar click cycloaddition to 





The alkyne-thiirane 2 was prepared from 4-hydroxythiophenol 4 as shown in Scheme 2. 
Selective S-alkylation of the commercially available 4-hydroxyphenol 4 with allyl bromide, and 
subsequent propargylation of the phenol, provided compound 6 in high yield. Oxidation of the 
sulfur and alkene moieties in 6 was achieved with excess m-CPBA to afford oxirane (±)-7 in 
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75% yield. Conversion of the epoxide to the thiirane (±)-2 was accomplished by thiourea 






























Ten different azides, synthesized using standard azidation methods24 and subjected to “click” 
cycloaddition with alkyne 2, furnished in high yields the triazolyl-thiiranes 3 (Table 1). We 
found that a mixed solvent system containing t-BuOH, water and THF (1:1:1) dissolved the 
alkyne and the azides and the reaction mixture proceeded smoothly to completion. The 
cycloaddition proceeded in a highly regioselective manner, consistent with known literature,6 giving 
only the 1,4-disubstituted 1,2,3 triazole as product. 
 
Table 1. Syntheses of triazole-thiiranes 3 
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Table 1. Continued 


















































aIsolated yields after flash column chromatography. 
 
TACE (TNF-α converting enzyme) is a zinc-dependent metalloproteinase whose active site 
domain is homologous to that of the MMPs. Potent inhibitors with dual MMP and TACE activity 
incorporating a butynyloxy tail with a different zinc-binding group (ZBG), were reported 
previously (Figure 3).25,26 Based on this observation, we synthesized the O-butynyloxy and 
O-pentynyloxy thiirane analogs for evaluation as gelatinase inhibitors. The synthetic route to 
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O-Alkylation of phenol 5 with 1-bromo-2-butyne and 1-bromo-2-pentyne gave compounds 
8a and 8b in high yields, respectively. Subsequent oxidation with m-CPBA provided oxiranes 
(±)-9 in poor yields, likely reflecting competitive over-oxidation occurring at the internal alkyne. 
Oxiranes 9a and 9b were treated separately with thiourea to give in good yields the thiiranes 
(±)-10a and (±)-10b. The inhibitory activity against MMP-2 of these thiiranes was evaluated in 




































Figure 4. Inhibitory activity against MMP-2 evaluated in vitro using a fluorimetric assay in 96-
well plate format. The compounds were assayed at 30 µM final concentration. The reaction was 
measured immediately after mixture of the enzyme and inhibitors (grey), and after 3 hour 
incubation of the enzyme with the inhibitors (black). 
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In general, at a concentration of 30 µM most of the triazole-thiiranes 3 were poor inhibitors 
of MMP-2. However, alkynes 2 and 10a, b were good inhibitors of MMP-2, especially following 
a 3 h preincubation. Assay of these three alkynes at a lower concentration (3 µM), also with a 3 h 
preincubation, showed that compounds 2 and 10b gave a 60% reduction in the activity of MMP-
2 (Figure 5). Compounds 2 and 10b are less active than compound 1, as evidenced by a 20- and 










no inhibitor 1 2 10a 10b
 
 
Figure 5. Inhibitory activity against MMP-2 evaluated in vitro using a fluorimetric assay in 96-
well plate format. The compounds were assayed at 3 µM final concentration. The reaction was 
measured immediately after mixture of the enzyme and inhibitors (grey), and after 3 hour 
incubation of the enzyme with the inhibitors (black). 
 
Table 2. IC50 of selected thiiranes 
Compound IC50 (µM) 
1 0.4 ± 0.1 
2 7 ± 2 
10a 26 ± 4 
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Conclusions  
 
Excessive catalytic activity by one of the metzincin zinc-dependent proteases (encompassing the 
MMP and ADAM families) is a characteristic of numerous human diseases.27,28 Accordingly, the 
incorporation of structural segments to attain sub-type selectivity is a focus of every current 
medicinal chemistry effort directed toward the inhibition of one of these proteases.29,30 Toward 
this objective, the mechanism-based thiirane inhibitor 1 is remarkable. It would appear that only 
members of the gelatinase sub-family of the MMPs (MMP-2 and MMP-9) are able to efficiently 
use their active site-glutamate for the deprotonation-dependent opening of the thiirane to liberate 
the caged thiolate as a stable ligand for the catalytic zinc atom. Contributing toward this 
mechanistic selectivity is the 4-phenoxyphenyl motif of 1, an established motif favoring 
selectivity toward those MMPs with small and hydrophobic S1’ pockets (such as MMP-2 and 
MMP-9). As is characteristic of many structure-activity relationships, however, the selection of a 
particular substituent reflects compromise. Here, the 4-phenoxyphenyl favorably contributes 
toward gelatinase selectivity, but imparts unacceptably poor water solubility to the molecule as a 
whole. 
The particular objective of this structure-activity study was the evaluation of triazole 
replacements for the 4-phenoxy segment, using Cu-catalyzed azide-alkyne cycloaddition to 
attain structural diversity. While the triazole replacement is certainly more polar than the phenyl 
that it replaces, we were aware that the gelatinase S1’ pocket tolerates well polar substitution at 
the para-position of this phenyl,31 and moreover tolerates well replacement of this same phenyl 
by small alkyl-substituted sulfonates. Accordingly, recognition of the greater polarity of the 
triazole was not foreseen as a barrier to the initiation of chemistry. Other possibilities might 
explain the low activity of the resulting triazole-containing inhibitors against MMP-2. The use of 
a two-atom (–CH2O–) link between the triazolyl and phenyl rings, arising from the 
alkynylmethoxy coupling partner in the cycloaddition, is one possible explanation. 
Triazolylmethyl inhibitors 3a–3j are better visualized as 4-phenylmethoxy mimetics, rather than 
4-phenoxyphenyl mimetics. Within the known structure-activity correlations for MMP-2 
inhibition (and also encompassing those for structure 1), the use of the 4-(phenylmethoxy)phenyl 
as an S1’ segment is inferior compared to the 4-phenoxyphenyl. 
The second notable structure-activity correlation is the significant MMP-2 inhibitory activity 
of the 4-alkynylmethoxy derivatives. The 4-alkynylmethoxyphenyl motif has precedent in 
metzincin protease inhibition design. When paired with many zinc-binding groups, the 4-alkyn-
ylmethoxyphenyl motif imparts selectivity towards ADAM protease inhibition, and against 
MMP inhibition.32-35 Nonetheless, in the course of a comprehensive SAR study of the 4-
alkynylmethoxyphenyl paired to thiol zinc-binding groups, Bandarage et al.25,36observed several 
inhibitors having this pairing that showed both MMP-2 and ADAM-17 inhibitory activity. Our 
structure-activity data for MMP-2 inhibition are consistent with their data. This structure-activity 
similarity raises the possibility that the alkynyloxyphenyl-substituted thiirane inhibitors 10a and 
10b may exert mechanism-based inhibition within the ADAM metzincin protease family. 
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Experimental Section 
 
General. All organic reagents were purchased from either Sigma-Aldrich Chemical Company 
(St Louis, MO, USA) or Acros Organics (Geel, Belgium), unless otherwise stated. All reactions 
were performed under an atmosphere of nitrogen, unless otherwise noted. 1H and 13C NMR 
spectra were recorded on a Varian UnityPlus 300, or a Varian INOVA-500 spectrometer (Varian 
Inc., Palo Alto, CA, USA). Chemical shifts (δ) are reported using TMS as an internal standard. 
Reactions were monitored by TLC using 0.20 µm E. Merck Silica Gel plates (60F254) with 
visualization of product bands by UV fluorescence (λ = 254 nm) and/or aqueous cerium sulfate 
staining, followed by heating. Flash chromatography was carried out with silica gel 60, 230–400 
mesh (0.040–0.063 µm particle size) purchased from EM Science (Gibbstown, NJ, USA). High-
resolution mass spectra were obtained at the Department of Chemistry and Biochemistry, 
University of Notre Dame by FAB ionization, using a JEOL AX505HA mass spectrometer or by 
ESI ionization, using a BRUKER microTOF II mass spectrometer. MMP-2 was purchased from 
Calbiochem (EMD Chemicals). The fluorogenic substrate (MOCAcPLGL(Dpa)AR-NH2) was 
purchased from Peptides International (Louisville, KY, USA). Substrate hydrolysis was 
measured with a Varian Cary Eclipse fluorescence spectrophotometer. 
 
Screening of MMP-2 inhibitors on 96-well plates  
Stock solutions of inhibitors (10 mM, 1 mM, and 100 µM) were prepared in DMSO. MOCAc-
Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 (Peptide Institute, Inc., Code MOC-3163-v) was 
reconstituted in DMSO to 1 mM final concentration. The reaction buffer (Buffer R) was 50 mM 
HEPES pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.01% Brij-35 and 1% DMSO. The MMP-2 
enzyme was diluted in Buffer R to a final concentration of 2 nM. The substrate concentration 
used in the assay was 10 µM. Inhibitors were evaluated at concentrations of either 30 µM or 3 
µM. The reaction volume was 200–210 µL. 2 µL of 1 mM fluorogenic peptide substrate was 
added to each well of a 96-well black microplate (Greiner bio-one, Cat. # 655209). In a separate 
1-mL 96 well-plate (VWR Cat # 40002-009) an appropriate volume of the concentrated inhibitor 
stock was added to each well followed by the addition of 500 µL of the 2 nM MMP-2 enzyme 
stock (e.g. 1.5 µL of 10 mM inhibitor stock solution, so as to give a final inhibitor concentration 
of 30 µM). The inhibitor solution and enzyme were mixed quickly with a multichannel 
micropipette (200 µL), and 200 µL enzyme/inhibitor mixture were transferred to the wells that 
contained the substrate drops in the 96-well black microplate, and mixed by pipetting up and 
down. The reaction was measured immediately after mixture of the enzyme and inhibitors, and 
after approximately 3 h incubation of the enzyme with the inhibitors. The change in fluorescence 
intensity in each well (using values for λexc = 328 nm and λem = 393 nm, and 5 nm excitation and 
emission slits) was measured over a 15 min interval. The change of the fluorescence intensity 
with time in the presence of the inhibitors was compared to one observed for the enzyme/DMSO 
control (slope assigned to 100% MMP-2 catalytic activity).  
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4-(Allylthio)phenol (5). To a stirred solution of 4-hydroxythiophenol 4 (5 g, 39.62 mmol) in 
DMF (25 mL) at ice-water temperature were added K2CO3 (5.5 g, 39.6 mmol) and allyl bromide 
(3.44 mL, 39.6 mmol). The reaction mixture was stirred for 15 min, and then allowed to warm 
overnight to room temperature with stirring. After addition of 1 M aqueous HCl, the mixture was 
extracted twice with EtOAc. The combined organic layers were washed with water and with 
brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by 
silica gel column chromatography (1/10 to 1/6 EtOAc:hexanes) to give 5 (6.3 g, 95%) as a white 
semi-solid. Its 1H and 13C NMR spectra and mass spectrum were identical with reported values.37 
Allyl[4-(prop-2-ynyloxy)phenyl]sulfane (6). A mixture of the 4-(Allylthio)phenol 5 (2.7 g, 16.4 
mmol), K2CO3 (4.6 g, 32 mmol) and propargyl bromide (3.6 g, 24.7 mmol) in dry acetone (30 
mL) was heated to reflux under nitrogen for 1.5 h. The reaction was concentrated in vacuo giving 
a yellow oil. The residue was taken in ethyl acetate, washed with water, dried over Na2SO4, and 
concentrated under reduced pressure. The resultant residue was purified by silica gel column 
chromatography to give 6 as a colorless oil (2.89 g, 85%): 1H NMR (500 MHz, CDCl3) δ 2.52 (t, 
J = 2.4 Hz, 1H), 3.43 (dt, J = 7.0, 1.1 Hz, 2H), 4.67 (d, J = 2.5 Hz, 2H), 4.98-5.04 (m, 2H), 5.84 
(m, 1H), 6.90 (m, 2H), 7.34 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 39.0, 55.8, 75.7, 78.3, 
115.3, 117.4, 127.1, 133.5, 133.9, 156.9; HRMS (FAB) calcd for C12H12OS (M+) 204.0609, 
found 204.0600. 
(±)-2-[[4-(Prop-2-ynyloxy)phenylsulfonyl]methyl]oxirane (7). To a stirred solution of the 
compound 6 (14.55 g, 71 mmol) in CH2Cl2 (300mL) was added m-CPBA (63.8 g , 284 mmol) at 
ice-water temperature, and the mixture was subsequently stirred at room temperature for 4 days. 
An additional amount of m-CPBA (16 g, 71 mmol) was added and stirred for another 4 days. The 
reaction was filtered and the filtrate was concentrated in vacuo. The residue was taken up in 
EtOAc and washed sequentially with a saturated Na2S2O3 solution, a saturated NaHCO3 solution, 
and water. The EtOAc solution was dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by silica chromatography to give epoxide 7 (13.5 g, 75%) as a 
white solid: 1H NMR (500 MHz, CDCl3) δ 2.45 (dd, J = 4.7, 2.3 Hz, 1H), 2.58 (t, J = 2.4 Hz, 
1H), 2.81 (m, 1H), 3.23-3.35 (m, 3H), 4.79 (d, J = 2.6 Hz, 2H), 7.13 (m, 2H), 7.90 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 45.8, 56.0, 59.5, 76.6, 77.1, 115.3, 130.2, 131.4, 161.7; HRMS 
(FAB) calcd for C12H12O4S (M+H+) 253.0535, found 253.0556. 
(±)-2-[[4-(Prop-2-ynyloxy)phenylsulfonyl]methyl]thiirane (2). To a stirred solution of epoxide 
7 (13.5 g, 53.5 mmol) in MeOH-CH2Cl2 (10:1, 200 mL) was added thiourea (10 g, 133 mmol) at 
room temperature, and the mixture was stirred overnight. After concentration under reduced 
pressure, the residue partitioned between ethyl acetate and water. The EtOAc layer was separated 
and washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue 
was purified by silica chromatography to give thiirane 2 (10.26 g, 72%) as a white solid: 1H 
NMR (500 MHz, CDCl3) δ 2.13 (dd, J = 4.8, 1.8 Hz, 1H), 2.52 (dd, J = 6.2, 1.8 Hz, 1H), 2.59 (d, 
J = 2.2 Hz, 1H), 3.01-3.19 (m, 2H), 3.53 (dd, J = 14.0, 5.4 Hz, 1H), 4.80 (d, J = 2.2 Hz, 2H), 
7.14 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 24.2, 26.1, 
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56.1, 62.6, 76.7, 77.3, 115.5, 130.5, 130.9, 161.9; HRMS (FAB) calcd for C12H12O3S2 (M+H+) 
269.0306, found 269.0324. 
The syntheses of the azides of Table 1 used literature precedent. The azides were made from the 
respective bromides by displacement with sodium azide (Entries 1–7)38-40 or from the amine by 
diazo-transfer reaction (Entries 8–10).3 
 
General procedure for the syntheses of triazole-thiiranes (3) 
To a solution of thiirane 2 (0.149 mmol, 1 eq.) and azide (0.17 mmol, 1.2 eq) in a 1:1:1 mixture 
of THF (1 mL), H2O (1 mL) and t-BuOH (1 mL) was added a freshly prepared CuSO4 solution 
(0.238 mL of a 0.125M solution in H2O, 20 mol%), followed by sodium ascorbate (0.238 mL of 
a 250 mM of freshly prepared solution in H2O, 40 mol%). The reaction mixture was vigorously 
stirred overnight at room temperature. After completion (monitored by TLC) the reaction 
mixture was filtered through celite and concentrated in vacuo and the residue was purified by 
flash column chromatography. 
(±)-1-Benzyl-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazole (3a). 
Yield 65%. 1H NMR (500 MHz, CDCl3) δ 2.10 (dd, J = 5.2, 1.8 Hz, 1H), 2.50 (dd, J = 6.2, 1.4 
Hz, 1H), 3.04 (dq, J = 7.8, 5.6 Hz, 1H), 3.14 (dd, J = 14.3, 7.9 Hz, 1H), 3.50 (dd, J = 14.2, 5.6 
Hz, 1H), 5.26 (s, 2H), 5.55 (s, 2H), 7.12 (d, J = 8.8 Hz, 2H), 7.28 (m, 2H), 7.38 (m, 3H), 7.56 (s, 
1H), 7.84 (d, J = 8.8 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 24.2, 26.1, 56.3, 62.2, 62.6, 115.4, 
122.9, 128.1, 128.9, 129.2, 130.6, 134.2, 143.2, 162.6; HRMS (FAB) calcd for C19H19N3O3S2 
(M+H+) 402.0946, found 402.0936. 
(±)-1-Phenethyl-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazole (3b). 
Yield 82%. 1H NMR (500 MHz, CDCl3) δ 2.12 (dd, J = 5.1, 1.8 Hz, 1H), 2.51 (dd, J = 6.2, 1.8 
Hz, 1H), 3.05 (m, 1H), 3.12-3.24 (m, 3H), 3.50 (dd, J = 14.1, 5.5 Hz, 1H), 4.61 (t, J = 7.3 Hz, 
2H), 5.25 (s, 2H), 7.06-7.13 (m, 4H), 7.25-7.27 (m, 3H), 7.34 (s, 1H), 7.85 (d, J = 8.8 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ 24.2, 26.1, 36.6, 51.8, 62.2, 62.6, 115.4, 123.3, 127.2, 128.6, 
128.8, 130.6, 136.7, 142.5, 162.6; HRMS (FAB) calcd for C20H21N3O3S2 (M+H+) 416.1103, 
found 416.1111. 
(±)-1-(3-Phenylpropyl)-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazole 
(3c). Yield 67%. 1H NMR (500 MHz, CDCl3) δ 2.10 (dd, J = 5.0, 1.8 Hz, 1H), 2.27 (m, 2H), 
2.50 (dd, J = 6.2, 1.8 Hz, 1H), 2.66 (t, J = 7.5 Hz, 2H), 3.03 (m, 1H), 3.16 (dd, J = 14.2, 7.8 Hz, 
1H), 3.49 (dd, J = 14.2, 5.6 Hz, 1H), 4.37 (t, J = 7.2 Hz, 2H), 5.29 (s, 2H), 7.14-7.17 (m, 4H), 
7.22 (m, 1H), 7.29 (m, 2H), 7.63 (s, 1H), 7.85 (d, J = 8.8 Hz, 2H); 13C NMR (125 MHz, CDCl3) 
δ 24.1, 26.1, 31.5, 32.4, 49.6, 62.2, 62.5, 115.3, 122.9, 126.3, 128.3, 128.6, 130.6, 139.9, 142.7, 
162.6; HRMS (FAB) calcd for C21H23N3O3S2 (M+H+) 430.1259, found 430.1257. 
(±)-6-[4-[[4-(Thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazol-1-yl]hexan-1-ol 
(3d). Yield 74%. 1H NMR (500 MHz, CDCl3) δ 1.25-1.44 (m, 6H), 1.52-1.58 (m, 2H), 1.94 (dt, 
J = 14.7, 7.3 Hz, 2H), 2.12 (dd, J = 5.0, 1.8 Hz, 1H), 2.52 (dd, J = 6.2, 1.4 Hz, 1H), 3.05 (m, 
1H), 3.17 (dd, J = 14.3, 7.9 Hz, 1H), 3.51 (dd, J = 14.2, 5.6 Hz, 1H), 3.62 (t, J = 6.5 Hz, 2H), 
4.39 (t, J = 7.1 Hz, 2H), 5.31 (s, 2H), 7.16 (d, J = 9.0 Hz, 2H), 7.63 (s, 1H), 7.86 (d, J = 9.0 Hz, 
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2H); 13C NMR (125 MHz, CDCl3) δ 24.1, 25.0, 26.0, 29.6, 30.1, 32.2, 50.3, 62.2, 62.3, 62.5, 
115.4, 122.9, 130.6, 142.7, 162.6; HRMS (FAB) calcd for C18H25N3O4S2 (M+H+) 412.1365, 
found 412.1386. 
(±)-4-[4-[[4-(Thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazol-1-yl]butan-1-ol 
(3e). Yield 58%. 1H NMR (500 MHz, CDCl3) δ 1.55-1.60 (m, 2H), 2.00-2.07 (m, 2H), 2.11 (dd, 
J = 5.2, 1.8 Hz, 1H), 2.50 (dd, J = 6.2, 1.8 Hz, 1H), 3.04 (m, 1H), 3.16 (dd, J = 14.2, 7.8 Hz, 
1H), 3.49 (dd, J = 14.2, 5.6 Hz, 1H), 3.68 (t, J = 6.2 Hz, 2H), 4.43 (t, J = 7.2 Hz, 2H), 5.28 (s, 
2H), 7.14 (d, J = 9.0 Hz, 2H), 7.67 (s, 1H), 7.84 (d, J = 9.0 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 24.1, 26.1, 26.9, 29.1, 50.3, 61.8, 62.2, 62.6, 115.4, 123.0, 130.6, 142.8, 162.6; HRMS 
(FAB) calcd for C16H21N3O4S2 (M+H+) 384.1052, found 384.1026. 
(±)-Ethyl 2-[4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazol-1-yl] 
acetate (3f). Yield 80%. 1H NMR (500 MHz, CDCl3) δ 1.30 (t, J = 7.2 Hz, 3H), 2.11 (dd, J = 
5.0, 1.7 Hz, 1H), 2.50 (dd, J = 6.0, 1.7 Hz, 1H), 3.03 (m, 1H), 3.14 (m, 1H), 3.51 (dd, J = 14.0, 
5.4 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 5.18 (s, 2H), 5.32 (s, 2H), 7.15 (d, J = 8.9 Hz, 2H), 7.84 
(m, 3H); 13C NMR (125 MHz, CDCl3) δ 14.0, 24.2, 26.1, 50.9, 62.1, 62.5, 62.6, 115.4, 124.5, 
130.6, 143.2, 162.6, 166.1; HRMS (FAB) calcd for C16H19N3O5S2 (M+H+) 398.0844, found 
398.0830. 
(±)-N,N-Dimethyl-2-[4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazol-1-
yl]acetamide (3g). Yield 62%. 1H NMR (500 MHz, CDCl3) δ 2.12 (dd, J = 5.2, 1.8 Hz, 1H), 
2.51 (dd, J = 6.0, 1.6 Hz, 1H), 3.02 (s, 3H), 3.05 (m, 1H), 3.11-3.16 (m, 1H), 3.15 (s, 3H), 3.53 
(dd, J = 14.2, 5.4 Hz, 1H), 5.26 (s, 2H), 5.32 (s, 2H), 7.16 (d, J = 9.0 Hz, 2H), 7.86 (m, 3H); 13C 
NMR (125 MHz, CDCl3) δ 24.2, 26.1, 34.9, 36.7, 50.9, 62.1, 62.6, 115.4, 125.2, 130.6, 142.8, 
162.6, 164.7, 169.4; HRMS (FAB) calcd for C16H20N4O4S2 (M+H+) 397.1004, found 397.1022. 
(±)-1-(Phenyl)-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazole (3h). 
Yield 95%. 1H NMR (500 MHz, CDCl3) δ 2.13 (dd, J = 5.2, 1.8 Hz, 1H), 2.52 (dd, J = 5.8, 1.4 
Hz, 1H), 3.06 (m, 1H), 3.17 (dd, J = 14.2, 8.0 Hz, 1H), 3.52 (dd, J = 14.2, 5.6 Hz, 1H), 5.40 (s, 
2H), 7.20 (d, J = 8.8 Hz, 2H), 7.47 (m, 1H), 7.55 (m, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.88 (d, J = 
9.0 Hz, 2H), 8.10 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 24.2, 26.1, 62.2, 62.6, 115.4, 120.6, 
121.1, 129.1, 129.9, 130.7, 130.8, 143.6, 162.6; HRMS (ESI) calcd for C18H17N3O3S2 (M+H+) 
388.0790, found 388.0787. 
(±)-1-(4-Chlorophenyl)-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-tri-
azole (3i). Yield 87%. 1H NMR (500 MHz, CDCl3) δ 2.13 (dd, J = 5.2, 1.6 Hz, 1H), 2.52 (dd, J 
= 6.2, 1.8 Hz, 1H), 3.06 (m, 1H), 3.18 (dd, J = 14.2, 7.8 Hz, 1H), 3.50 (dd, J = 14.2, 5.6 Hz, 1H), 
5.39 (s, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.88 (d, 
J = 8.6 Hz, 2H), 8.08 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 24.2, 26.1, 62.1, 62.6, 115.4, 
121.1, 121.8, 130.0, 130.7, 130.8, 134.9, 135.2, 143.9, 162.5; HRMS (FAB) calcd for 
C18H16ClN3O3S2 (M+H+) 422.0400, found 422.0407. 
(±)-1-(4-Fluorophenyl)-4-[[4-(thiiran-2-ylmethylsulfonyl)phenoxy]methyl]-1H-1,2,3-triazole 
(3j). Yield 95%. 1H NMR (500 MHz, CDCl3) δ 2.13 (dd, J = 5.2, 1.8 Hz, 1H), 2.52 (dd, J = 6.0, 
1.4 Hz, 1H), 3.06 (m, 1H), 3.18 (dd, J = 14.2, 7.9 Hz, 1H), 3.51 (dd, J = 14.2, 5.6 Hz, 1H), 5.39 
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(s, 2H), 7.18-7.24 (m, 4H), 7.73 (m, 2H), 7.88 (d, J = 8.8 Hz, 2H), 8.05 (s, 1H); 13C NMR (125 
MHz, CDCl3) δ 24.2, 26.1, 62.1, 62.6, 115.4, 116.7, 116.9, 121.4, 122.6, 122.7, 130.7, 130.7, 




A mixture of 4-(Allylthio)phenol 5 (595 mg, 3.5 mmol), K2CO3 (1.0 g, 7.1 mmol) and 1-Bromo-
2-butyne (0.47 mL, 5.3 mmol) in dry acetonitrile (30 mL) was heated to reflux under nitrogen for 
1.5 h. The reaction was concentrated in vacuo giving a yellow oil. The residue was taken in ethyl 
acetate, washed with water, dried over Na2SO4, and concentrated under reduced pressure. The 
residue was purified by silica gel column chromatography to give 8a as a colorless oil (610 mg, 
78%): 1H NMR (500 MHz, CDCl3) δ 1.86 (t, J = 2.4 Hz, 3H), 3.44 (dt, J = 7.2, 1.1 Hz, 2H), 4.63 
(t, J = 2.2 Hz, 2H), 4.99-5.03 (m, 2H), 5.84 (m, 1H), 6.90 (m, 2H), 7.34 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ 3.7, 39.1, 56.5, 73.8, 83.9, 115.3, 117.3, 126.6, 133.5, 133.9, 136.0, 157.2; 
HRMS (FAB) calcd for C13H14OS (M+) 218.0765, found 218.0756. 
Allyl-[4-(pent-2-ynyloxy)phenyl]sulfane (8b). Prepared from 5 (603 mg, 3.6 mmol) as described 
for 8a, except 1-bromo-2-pentyne substituted 1-bromo-2-butyne in the procedure to afford 650 
mg (77%) of 8b: 1H NMR (500 MHz, CDCl3) δ 1.13 (t, J = 7.5 Hz, 3H), 2.23 (qt, J = 7.5, 2.1 
Hz, 2H), 3.44 (dt, J = 6.9, 1.0 Hz, 2H), 4.65 (t, J = 2.1 Hz, 2H), 4.98-5.02 (m, 2H), 5.84 (m, 1H), 
6.89 (m, 2H), 7.34 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 12.5, 13.6, 39.1, 56.5, 73.9, 89.7, 
115.3, 117.3, 126.5, 133.5, 133.9, 136.0, 157.2; HRMS (FAB) calcd for C14H16OS (M+) 
232.0922, found 232.0939. 
(±)-2-[[4-(But-2-ynyloxy)phenylsulfonyl]methyl]oxirane (9a). Prepared from 8a (0.580 mg, 
2.65mmol) as described for 7 affording 155 mg (22%) of the epoxide 9a as a white solid: 1H 
NMR (500 MHz, CDCl3) δ 1.87 (t, J = 2.3 Hz, 3H), 2.46 (dd, J = 4.8, 2.4 Hz, 1H), 2.81 (t, J = 
4.3 Hz, 1H), 3.23-3.36 (m, 3H), 4.74 (q, J = 2.3 Hz, 2H), 7.11 (m, 2H), 7.88 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 3.6, 45.9, 56.8, 59.6, 72.7, 85.0, 115.4, 130.2, 131.0, 162.2; HRMS (FAB) 
calcd for C13H14O4S (M+H+) 267.0691, found 267.0671. 
(±)-2-[[4-(Pent-2-ynyloxy)phenylsulfonyl]methyl]oxirane (9b). Prepared from 8b (0.580 mg, 
2.65mmol) as described for 7 afforded 123 mg (18%) of the epoxide 9b as a white solid: 1H 
NMR (500 MHz, CDCl3) δ 1.13 (t, J = 7.6 Hz, 3H), 2.23 (qt, J = 7.5, 2.2 Hz, 2H), 2.45 (dd, J = 
4.8, 2.1 Hz, 1H), 2.80 (m, 1H), 3.20-3.38 (m, 3H), 4.76 (t, J = 2.2 Hz, 2H), 7.11 (d, J = 8.8 Hz, 
2H), 7.88 (d, J = 8.8 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 12.4, 13.5, 45.9, 56.9, 59.6, 72.9, 
90.8, 115.5, 130.2, 131.1, 162.2; HRMS (FAB) calcd for C14H16O4S (M+H+) 281.0848, found 
281.0833. 
(±)-2-[[4-(But-2-ynyloxy)phenylsulfonyl]methyl]thiirane (10a). Prepared from 9a (0.140 g, 
0.52 mmol) as described for 2 affording 113 mg (76%) of the thiirane 10a as a white solid: 1H 
NMR (500 MHz, CDCl3) δ 1.87 (t, J = 2.4 Hz, 3H), 2.14 (dd, J = 5.2, 1.8 Hz, 1H), 2.52 (m, 1H), 
3.06 (m, 1H), 3.15 (dd, J = 14.2, 8.0 Hz, 1H), 3.54 (dd, J = 14.1, 5.7 Hz, 1H), 4.75 (q, J = 2.4 
Hz, 2H), 7.11 (d, J = 9.0 Hz, 2H), 7.86 (d, J = 9.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 3.6, 
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24.2, 26.1, 56.8, 62.6, 72.7, 85.0, 115.4, 130.4, 130.4, 162.2; HRMS (FAB) calcd for C13H14O3S2 
(M+H+) 283.0463, found 283.0455. 
 (±)-2-[[4-(Pent-2-ynyloxy)phenylsulfonyl]methyl]thiirane (10b). Prepared from 9b (0.11 g, 
0.39 mmol) as described for 2 affording 78 mg (67%) of the thiirane 10b as a white solid: 1H 
NMR (500 MHz, CDCl3) δ 1.14 (t, J = 7.6 Hz, 3H), 2.13 (dd, J = 5.1, 1.7 Hz, 1H), 2.24 (qt, J = 
7.5, 2.2 Hz, 1H), 2.52 (dd, J = 6.0, 1.8 Hz, 1H), 3.06 (m, 1H), 3.15 (dd, J = 14.2, 8.0 Hz, 1H), 
3.54 (dd, J = 14.2, 5.2 Hz, 1H), 4.77 (t, J = 2.2 Hz, 2H), 7.12 (d, J = 8.8 Hz, 2H), 7.86 (d, J = 8.8 
Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 12.4, 13.5, 24.3, 26.1, 56.9, 62.6, 72.9, 90.8, 115.5, 
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